Hanmi-Genentech Deal Proves Korea Can Originate Global Obesity Drugs

The Number That Should Startle Everyone

A $190 million upfront payment. A ceiling of $2.3 billion when development milestones, regulatory approvals, and commercial sales are all tallied. A royalty stream on top.

This is Hanmi Pharma’s deal with Genentech, the American arm of Switzerland’s Roche, for its obesity drug candidate HM17321. On paper, it is Korea’s largest pharma licensing agreement in history. But the headline number is almost beside the point.

The real story is what the deal proves: that a Korean company can identify a genuine scientific gap in the global obesity drug market, build a first-in-class molecule to fill it, and sell it to one of the world’s most formidable pharma organizations on its own terms.

For years, Korea’s pharmaceutical industry has been described — fairly or not — as a master of fast-following. Companies perfected the art of refining existing molecules, manufacturing at scale, and bringing biosimilars and generic versions to market with remarkable speed. That model is legitimate and lucrative. It is also increasingly crowded, and it never produced a molecule with truly differentiated mechanism-of-action that shaped global prescribing standards.

HM17321 changes that conversation.

The Science Nobody Saw Coming

HM17321 is a UCN2 analogue — a peptide that mimics the activity of urocortin-2, a naturally occurring protein in the human body. Genentech and Hanmi have positioned it firmly in the non-incretin camp, meaning it works through an entirely different biological pathway than the GLP-1 receptor agonists that currently dominate the obesity drug market.

This distinction matters more than corporate press releases usually admit.

The GLP-1 class — represented by Eli Lilly’s tirzepatide (Zepbound, Mounjaro) and Novo Nordisk’s semaglutide (Wegovy, Ozempic) — has generated an industry worth hundreds of billions. But these drugs share a well-documented limitation: patients lose weight, but they also lose lean muscle mass along with fat. Clinical data consistently shows the proportion of fat-to-muscle loss during GLP-1 treatment, and preserving muscle during weight reduction remains an active area of medical concern, especially for aging populations and patients with metabolic comorbidities.

Hanmi’s preclinical data, presented here for the first time in full context, suggests HM17321 achieves what the company calls simultaneous fat reduction and muscle preservation. The company has not yet released peer-reviewed clinical results — Phase 1 data is still being collected in healthy volunteers and obese patients — so the claim remains unvalidated in humans. But the direction of the science is clear, and it maps directly onto the acknowledged weakness in the current obesity drug landscape.

The non-incretin angle also opens the door to combination therapy. Genentech’s Boris L. Zittra, who oversees corporate business development at Roche, explicitly stated that the company plans to explore HM17321 in fixed-dose combinations with existing incretin-based treatments. If HM17321 proves its muscle-sparing effect in Phase 2 and 3 trials, the question shifts from whether it can compete with GLP-1 drugs to whether it can enhance them.

That is a far more valuable position in the market than simply being another option in an increasingly saturated pipeline.

Why Genentech — and What It Signals

Genentech is not a casual buyer. It is the innovation engine of the Roche group, home to some of oncology’s most transformative drugs, and it approaches obesity therapeutics with considerable seriousness. Roche already holds a licensing relationship with Voyager Therapeutics for an RNA-based obesity drug (VMX01), and Genentech has invested heavily in its own metabolic disease pipeline. The company did not sign a $190 million check for an unproven concept.

What Genentech saw in HM17321, specifically, is difficult to confirm without access to the private due diligence process. But the choice of partner is revealing. Genentech could have pursued a UCN2 analogue through its own internal discovery program or licensed from a Western biotech. Instead, it chose Hanmi — a Korean company with a Phase 1 trial already underway and regulatory acceptance from the U.S. FDA. That decision reflects confidence in Hanmi’s preclinical package and its ability to execute early clinical development, which is itself a significant endorsement of Korean CRO capabilities.

For Eli Lilly and Novo Nordisk, the signal is less about immediate competitive threat and more about strategic diversification. Both companies know their dominance faces eventual erosion — not from a single competitor but from the cumulative effect of multiple mechanism-of-action entrants. A drug that addresses lean mass preservation through a non-incretin pathway is precisely the kind of molecule that forces them to defend their positions beyond scale and brand recognition.

The combination strategy Genentech is pursuing effectively turns HM17321 into a potential complement to, rather than a direct replacement for, existing GLP-1 therapies. That could make it a product both sides want — a scenario that benefits Hanmi enormously in terms of negotiating leverage and long-term royalty upside.

What Happens Next

Hanmi holds the IND from the U.S. FDA, granted in November 2025, and is currently running Phase 1 safety and pharmacokinetics studies. Upon completion, development responsibility transfers to Genentech for Phase 2 and beyond. This is a standard large-company licensing structure, but the timeline is still years away from any regulatory outcome.

The financial math, however, is already tangible. Hanmi receives $190 million upfront, which immediately strengthens its balance sheet and funds its broader pipeline. The milestone payments — spread across Phase 2 initiation, Phase 3 starts, regulatory approvals in major markets, and sales thresholds — represent a ladder that could add roughly $2.1 billion more over the coming decade if the drug succeeds commercially. Royalties on peak sales would be added on top, though the exact rate was not disclosed in the announcement.

For the Korean biotech sector, the broader implication is structural. Hanmi proved that a company headquartered outside the traditional Western pharma centers can originate a novel mechanism, build credible preclinical and early clinical data, and attract the world’s most prestigious drug developers as partners. That pattern, if replicated, shifts how global pharma views Korean R&D — not as a low-cost development extension but as a source of proprietary scientific asset creation.

There are, of course, substantial risks. Phase 1 data has not yet been released, and many first-in-class obesity candidates fail at this stage. The muscle-preservation claim, if borne out, will face intense scrutiny from regulators and competitors alike. And the GLP-1 market, despite its challenges, still commands enormous pricing power and infrastructure that any new entrant must overcome.

But the deal itself is real. The science is specific. And the message from Seoul is unmistakable: Korea is no longer just manufacturing the future of medicine. It is originating it.